Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: a Multicenter, Retrospective Study

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine

This is a retrospective study aiming to explore the efficacy and safety of Pyrotinib plus Vinorelbine versus Lapatinib plus Capecitabine in patients with previously treated HER2-positive metastatic breast cancer.

Inclusion Criteria:

• HER2+ MBC patients scored +3 by immunohistochemical (IHC) analysis or scored +2 and the result of fluorescence in situ hybridization was positive.
• Patients were previously treated with trastuzumab in the advanced setting and a taxane in any setting.
• Patients received lapatinib (750-1,250 mg/day) plus capecitabine (1,500-2,000 mg/m2) or pyrotinib (320-400 mg/day) plus vinorelbine (25mg/ m2 intravenously or 60 mg/m2 orally on days 1 and 8 per 21 days) for at least one cycle, starting from Jun 2015 to Jan 2021.
• Patients had complete medical records. All data were retrospectively collected from medical records of individual institutions.

Exclusion Criteria:

• Incomplete medical history